We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amarin Corporation (AMRN - Free Report) reported a loss of 4 cents per share for the first quarter of 2025, which was significantly narrower than the Zacks Consensus Estimate of a loss of $1.12. The company had reported a loss of 2 cents per share in the year-ago quarter.
Excluding stock-based compensation expense and the American Depositary Shares (“ADS”) ratio change fees, the company incurred an adjusted loss of 2 cents per share in the first quarter of 2025 compared with an adjusted loss of 1 cent reported in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Total revenues in the first quarter were $42 million, which beat the Zacks Consensus Estimate of $40 million. However, revenues declined around 26% from the year-ago quarter’s levels, owing to lower product revenues.
Year to date, shares of Amarin have increased 5% against the industry’s decline of 8%.
Image Source: Zacks Investment Research
AMRN’s Q1 Earnings in Detail
Net product revenues from Vascepa, the company’s sole marketed drug, in the first quarter were $41 million, down 25.7% year over year.
U.S. product revenues from Vascepa totaled $35.7 million, declining almost 25.8% from the year-ago quarter’s level as rising generic competition continued to hurt sales volumes and price. The drug’s U.S. sales beat our model estimate of $22.1 million.
Product revenues from Vazkepa (Vascepa’s brand name in Europe) in the European market totaled $5.4 million compared with $1.9 million reported in the year-ago quarter. Revenues in the rest of the world were $0.1 million compared with $5.2 million reported in the year-ago quarter.
Licensing and royalty revenues came in at almost $1 million in the first quarter compared with $1.4 million reported in the year-ago period.
Selling, general and administrative expenses totaled $36.6 million, down almost 8.3% year over year due to cost optimization efforts.
Research and development expenses totaled $5.3 million, down around 5.4% year over year.
Amarin ended the first quarter with cash and investments of $281.8 million compared with $294.2 million reported in the quarter that ended December 2024.
AMRN's Recent Ratio Change Plan
With effect from April 11, 2025, Amarin initiated a ratio change on its American Depositary Shares (“ADS”) from one ADS representing one ordinary share to the new ratio of one ADS representing 20 ordinary shares.
Following the successful completion of the ratio change, the company regained compliance with the Nasdaq continued listing standard for the minimum share price of the Nasdaq Listing Qualifications.
Amarin Corporation PLC Price, Consensus and EPS Surprise
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $6.30 to $6.36 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.85 to $7.14. Year to date, shares of ANIP have rallied 28.2%.
ANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.32%.
In the past 60 days, estimates for Intellia Therapeutics’ loss per share have narrowed from $4.75 to $4.62 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.68 to $4.62. Year to date, shares of NTLA have plunged 37.4%.
NTLA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 5.37%.
In the past 60 days, estimates for Beam Therapeutics’ loss per share have narrowed from $4.45 to $4.27 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.94 to $4.80. Year to date, shares of BEAM have plunged 34.6%.
BEAM’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average negative surprise being 3.14%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
Amarin Corporation (AMRN - Free Report) reported a loss of 4 cents per share for the first quarter of 2025, which was significantly narrower than the Zacks Consensus Estimate of a loss of $1.12. The company had reported a loss of 2 cents per share in the year-ago quarter.
Excluding stock-based compensation expense and the American Depositary Shares (“ADS”) ratio change fees, the company incurred an adjusted loss of 2 cents per share in the first quarter of 2025 compared with an adjusted loss of 1 cent reported in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Total revenues in the first quarter were $42 million, which beat the Zacks Consensus Estimate of $40 million. However, revenues declined around 26% from the year-ago quarter’s levels, owing to lower product revenues.
Year to date, shares of Amarin have increased 5% against the industry’s decline of 8%.
Image Source: Zacks Investment Research
AMRN’s Q1 Earnings in Detail
Net product revenues from Vascepa, the company’s sole marketed drug, in the first quarter were $41 million, down 25.7% year over year.
U.S. product revenues from Vascepa totaled $35.7 million, declining almost 25.8% from the year-ago quarter’s level as rising generic competition continued to hurt sales volumes and price. The drug’s U.S. sales beat our model estimate of $22.1 million.
Product revenues from Vazkepa (Vascepa’s brand name in Europe) in the European market totaled $5.4 million compared with $1.9 million reported in the year-ago quarter. Revenues in the rest of the world were $0.1 million compared with $5.2 million reported in the year-ago quarter.
Licensing and royalty revenues came in at almost $1 million in the first quarter compared with $1.4 million reported in the year-ago period.
Selling, general and administrative expenses totaled $36.6 million, down almost 8.3% year over year due to cost optimization efforts.
Research and development expenses totaled $5.3 million, down around 5.4% year over year.
Amarin ended the first quarter with cash and investments of $281.8 million compared with $294.2 million reported in the quarter that ended December 2024.
AMRN's Recent Ratio Change Plan
With effect from April 11, 2025, Amarin initiated a ratio change on its American Depositary Shares (“ADS”) from one ADS representing one ordinary share to the new ratio of one ADS representing 20 ordinary shares.
Following the successful completion of the ratio change, the company regained compliance with the Nasdaq continued listing standard for the minimum share price of the Nasdaq Listing Qualifications.
Amarin Corporation PLC Price, Consensus and EPS Surprise
Amarin Corporation PLC price-consensus-eps-surprise-chart | Amarin Corporation PLC Quote
AMRN's Zacks Rank & Stocks to Consider
Amarin currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Intellia Therapeutics, Inc. (NTLA - Free Report) and Beam Therapeutics Inc. (BEAM - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $6.30 to $6.36 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.85 to $7.14. Year to date, shares of ANIP have rallied 28.2%.
ANIP’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 17.32%.
In the past 60 days, estimates for Intellia Therapeutics’ loss per share have narrowed from $4.75 to $4.62 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.68 to $4.62. Year to date, shares of NTLA have plunged 37.4%.
NTLA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 5.37%.
In the past 60 days, estimates for Beam Therapeutics’ loss per share have narrowed from $4.45 to $4.27 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.94 to $4.80. Year to date, shares of BEAM have plunged 34.6%.
BEAM’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average negative surprise being 3.14%.